Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia
Introduction: Flumatinib, a highly selective ABL kinase inhibitor, exhibits stronger inhibition of intracellular BCR-ABL tyrosine kinase activity, compared to Imatinib. However, there is limited research comparing the real-world efficacy and safety of flumatinib and dasatinib in patients with Philad...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924000130 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846113642727079936 |
|---|---|
| author | Qian Liu Tie Rong Bian Zhi Yuan Li Hong Yun Xing |
| author_facet | Qian Liu Tie Rong Bian Zhi Yuan Li Hong Yun Xing |
| author_sort | Qian Liu |
| collection | DOAJ |
| description | Introduction: Flumatinib, a highly selective ABL kinase inhibitor, exhibits stronger inhibition of intracellular BCR-ABL tyrosine kinase activity, compared to Imatinib. However, there is limited research comparing the real-world efficacy and safety of flumatinib and dasatinib in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Objective: Investigating the differences in therapeutic efficacy and safety between flumatinib and dasatinib in combination with multi-drug chemotherapy for the treatment of newly diagnosed Ph+ ALL. Method: In this study, we assessed 43 patients with newly diagnosed Ph+ ALL (20 in the flumatinib group, 23 in the dasatinib group). Results: There were no significant differences in gender, age, fusion gene type, initial blood routine, bone marrow blast cell ratio or chromosome karyotype between the two groups. Within 1 month, there were no significant differences in the complete response (CR), major molecular response (MMR) or minimal residual disease (MRD) negativity rate between the flumatinib and dasatinib groups. Similarly, within 3 months, there were no significant differences in CR or MMR rates between the two groups. However, the rates of complete molecular response (CMR) and MRD negativity within 3 months were significantly higher in the flumatinib group, compared to the dasatinib group (P < 0.05). Additionally, the flumatinib group exhibited fewer adverse reactions compared to the dasatinib group. Conclusion: These findings suggest that flumatinib is a safe and effective tyrosine kinase inhibitor (TKI) for achieving CMR and MRD negativity in patients with Ph+ ALL, as supported by this small series of patients. |
| format | Article |
| id | doaj-art-511c18057fd14c84a5d79b94dd1ae01b |
| institution | Kabale University |
| issn | 2531-1379 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj-art-511c18057fd14c84a5d79b94dd1ae01b2024-12-21T04:29:33ZengElsevierHematology, Transfusion and Cell Therapy2531-13792024-12-0146S71S78Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemiaQian Liu0Tie Rong Bian1Zhi Yuan Li2Hong Yun Xing3Affiliated Hospital of Southwest Medical University, Luzhou, ChinaAffiliated Hospital of Southwest Medical University, Luzhou, ChinaAffiliated Hospital of Southwest Medical University, Luzhou, ChinaCorresponding author at: Affiliated Hospital of Southwest Medical University, Luzhou, China.; Affiliated Hospital of Southwest Medical University, Luzhou, ChinaIntroduction: Flumatinib, a highly selective ABL kinase inhibitor, exhibits stronger inhibition of intracellular BCR-ABL tyrosine kinase activity, compared to Imatinib. However, there is limited research comparing the real-world efficacy and safety of flumatinib and dasatinib in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Objective: Investigating the differences in therapeutic efficacy and safety between flumatinib and dasatinib in combination with multi-drug chemotherapy for the treatment of newly diagnosed Ph+ ALL. Method: In this study, we assessed 43 patients with newly diagnosed Ph+ ALL (20 in the flumatinib group, 23 in the dasatinib group). Results: There were no significant differences in gender, age, fusion gene type, initial blood routine, bone marrow blast cell ratio or chromosome karyotype between the two groups. Within 1 month, there were no significant differences in the complete response (CR), major molecular response (MMR) or minimal residual disease (MRD) negativity rate between the flumatinib and dasatinib groups. Similarly, within 3 months, there were no significant differences in CR or MMR rates between the two groups. However, the rates of complete molecular response (CMR) and MRD negativity within 3 months were significantly higher in the flumatinib group, compared to the dasatinib group (P < 0.05). Additionally, the flumatinib group exhibited fewer adverse reactions compared to the dasatinib group. Conclusion: These findings suggest that flumatinib is a safe and effective tyrosine kinase inhibitor (TKI) for achieving CMR and MRD negativity in patients with Ph+ ALL, as supported by this small series of patients.http://www.sciencedirect.com/science/article/pii/S2531137924000130Philadelphia chromosome-positive Acute lymphoblastic leukemiaFlumatinibDasatinibEfficacyAdverse reactions |
| spellingShingle | Qian Liu Tie Rong Bian Zhi Yuan Li Hong Yun Xing Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia Hematology, Transfusion and Cell Therapy Philadelphia chromosome-positive Acute lymphoblastic leukemia Flumatinib Dasatinib Efficacy Adverse reactions |
| title | Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia |
| title_full | Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia |
| title_fullStr | Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia |
| title_full_unstemmed | Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia |
| title_short | Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia |
| title_sort | clinical efficacy and safety of flumatinib versus dasatinib combined with multi drug chemotherapy in adults with philadelphia positive acute lymphoblastic leukemia |
| topic | Philadelphia chromosome-positive Acute lymphoblastic leukemia Flumatinib Dasatinib Efficacy Adverse reactions |
| url | http://www.sciencedirect.com/science/article/pii/S2531137924000130 |
| work_keys_str_mv | AT qianliu clinicalefficacyandsafetyofflumatinibversusdasatinibcombinedwithmultidrugchemotherapyinadultswithphiladelphiapositiveacutelymphoblasticleukemia AT tierongbian clinicalefficacyandsafetyofflumatinibversusdasatinibcombinedwithmultidrugchemotherapyinadultswithphiladelphiapositiveacutelymphoblasticleukemia AT zhiyuanli clinicalefficacyandsafetyofflumatinibversusdasatinibcombinedwithmultidrugchemotherapyinadultswithphiladelphiapositiveacutelymphoblasticleukemia AT hongyunxing clinicalefficacyandsafetyofflumatinibversusdasatinibcombinedwithmultidrugchemotherapyinadultswithphiladelphiapositiveacutelymphoblasticleukemia |